B O O K - American College of Rheumatology

Upon completion of this session, participants should be able to:
• review the disease process of systemic lupus erythematosus
and juvenile idiopathic arthritis and the most common
medications utilized
• discuss age appropriate methods to educate children and
adolescents regarding SLE and JIA
• discuss age appropriate methods to educate children and
adolescents regarding common treatments used for SLE and
JIA
• identify available age appropriate materials and resources for
patient, family, and educators use
ACR Clinical Symposium
11:00 AM - 12:30 PM
B406
2010 ACR Recommendations for the Treatment of
Juvenile Idiopathic Arthritis P PS
Moderator: Liana Fraenkel, MD, MPH; Yale University; Newtown,
CT
11:00 AM
ACR Recommendations for the Treatment of Juvenile Idiopathic
Arthritis
Timothy Beukelman, MD, MSCE; University of Alabama-
Birmingham; Birmingham, AL
12:00 PM
Panel Discussion
Timothy Beukelman, MD, MSCE; University of Alabama-
Birmingham; Birmingham, AL
Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;
Cincinnati, OH
Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,
NY
Session Overview:
Major advances in treatment over the last 15 years have
greatly improved outcomes for children with juvenile idiopathic
arthritis, yet there are no prior validated guidelines offering
recommendations for the safest and most effective treatment
of juvenile idiopathic arthritis. Clinical practice guidelines are an
important way to promote effective care and to improve patient
outcomes. This symposium will present the methodology and
results of the newly developed evidence and consensus-based
ACR recommendations for the treatment of juvenile idiopathic
arthritis and seek public feedback and discussion.
Upon completion of this session, participants should be able to:
• describe the recommended treatment approach for different
juvenile idiopathic arthritis phenotypes: 4 or fewer affected
joints; 5 or more affected joints; presence of sacroiliitis;
systemic arthritis
• apply the recommended indications for biologic agents in the
treatment of juvenile idiopathic arthritis
• review the recommendations for monitoring of adverse
effects of therapeutics in juvenile idiopathic arthritis
ACR Concurrent Abstract Sessions
11:00 AM – 12:30 PM
A410
Antiphospholipid Syndrome II
Moderators: Silvia Pierangeli, MD; University of Texas Medical
Branch, Galeston, TX
Robert A.S. Roubey, MD; University of North Carolina; Chapel
Hill, NC
11:00 AM
2250. Evaluation of ‘Non-Criteria” Antiphospholipid (aPL)
Assays at a Wet Workshop during the 13th International
Congress on Antiphospholipid Antibodies.
Roger Albesa 1 , Victoria Nelson 1 , Zakera Shums 1 , Gary Norman 1 ,
X.-X. Gu 2 , Jacob Rand 2 , Walter Binder 1 , Bas deLaat 4 and Silvia
S. Pierangeli 3 , 1 INOVA Diagnostics, San Diego, CA, 2 Montefiore,
Albert Einstein School of Medicine, New York, NY, 3 Univ of TX
Med Branch, Galveston, Galveston, TX, 4 Utretch Medical Center,
Utrecht, The Netherlands
11:15 AM
2251. Evaluation of the Performance of Monoclonal and
Polyclonal Antibody Standards in Different Assays for the
Detection of Antiphospholipid (aPL) Antibodies: Report
of a Wet Workshop at the 13th International Congress on
Antiphospholipid Antibodies.
Ricardo Forastiero 8 , Elizabeth Papalardo 6 , Michael Watkins 1 ,
Hoang Nguyen 1 , Maria Crisostomo 1 , Wendy Vandam 1 , JOel
Hardy 1 , Roger Albesa 2 , Victoria Nelson 2 , Zakera Shums 2 , Gary
Norman 2 , Walter Binder 2 , Kerrie Morin 3 , Catherine Kirbach 3 ,
Karl Mattias 4 , Gabriella Lakos 5 and Sivia S. Pierangeli 7 , 1Bio-Rad
Laboratories, Hercules, CA, 2 INOVA Diagnostics, San Diego, Ca,
3
Instrumentation Laboratories, Bedford, MA, 4 Phadia GMBH,
Freiburg, Germany, 5 TherTest, Lombard, IL, 6 Univ of TX Med
Branch, Galveston, Galveston, TX, 7 Univ of TX Med Branch,
Galveston, TX, 8 Universidad Favaloro, Buenos Aires, Argentina
11:30 AM
2252. Comparative Evaluation of Different Immunoassays
for the Detection of Antiphospholipid Antibodies: Report of
a Wet Workshop during the 13th International Congress on
Antiphospholipid Antibodies.
Ricardo Forastiero 9 , Elizabeth Papalardo 8 , Kerrie Morin 4 ,
Catherine Quirbach 4 , Gabriella Lakos 6 , Karl Mattias 5 , Roger
Albesa 3 , Victoria Nelson 3 , Zakera Shums 3 , Gary Norman 3 ,
Walter Binder 3 , Bruno Larida 1 , Maria Crisostomo 2 , Michael
Watkins 2 , Hoang Nguyen 2 , Wendy Vandam 2 , Joel Hardy 2 and
Silvia S. Pierangeli 7 , 1 Bio-Rad Laboratories, Hercules, CA, 2 Bio-
Rad Laboratories, Her, 3 INOVA Diagnostics, San Diego, CA,
4
Instrumentation Laboratories, Bedford, MA, 5 Phadia GMBH,
Freiburg, Germany, 6 TheraTest Laboratories, Lombard, IL, 7 Univ
of TX Med Branch, Galveston, Galveston, TX, 8 Univ of TX Med
Branch, Galveston, TX, 9 Universidad Favaloro, Buenos Aires
Argentina
11:45 AM
2253. Elevated Cytokines and Chemokine Levels in
Antiphospholipid Antibody (aPL)-Positive Patients.
Vijaya L. Murthy, Shraddha Jatwani, Renan A. Aguilar-Valenzuela,
Ellis D. Doan, Elizabeth Papalardo, Emilio B. González and Silvia
S. Pierangeli, University of Texas Medical Branch, Galveston, TX
thursday
2010 Program Book 143